ReviewSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2022
A review on benefits of quercetin in hyperuricemia and gouty arthritis.
Review in Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- The effect of Quercetin supplementation on hyperuricemia-related biochemical and renal outcomes in animal models: a systematic review and meta-analysis.Journal of health, population, and nutrition · 2026Pooled it
- Article
- Uric Acid as a Redox Switch in Gout: Linking Xanthine Oxidoreductase-Derived ROS, NLRP3 Inflammasome Activation and Emerging Ferroptotic Mechanisms.Antioxidants (Basel, Switzerland) · 2026Review
- Engineering technology of implantable galvanic cells for silencing the bone-neural axis in gouty arthritis therapy.Nature communications · 2026Article
- [Association of metabolic syndrome and its components with gout: an analysis based on a large-scale health survey database].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2026Article
- Correlation analysis of PGC-1β, HIF-1α and RETN with the degree of joint destruction in gouty arthritis.Journal of medical biochemistry · 2026Article
- Flavonoid Interactions with Renal Organic Anion Transporters OAT1 and OAT3: Structure-Activity Relationships and Clinical Implications.International journal of molecular sciences · 2026Review
- Correlation analysis between the prevalence of hyperuricemia and the triglyceride-glucose index in adult patients with brucellosis.BMC infectious diseases · 2026Article
- Quercetin in metabolic diseases: mechanisms, therapeutics, and multidimensional frontiers.Frontiers in endocrinology · 2026Review
- Baseline Risk Factors and Predictive Nomogram for Short-Term Persistent Hyperuricemia Following Laparoscopic Sleeve Gastrectomy: A Dual Center Study.Obesity surgery · 2025Article
- Article
- Synergistic strength: unleashing exercise and polyphenols against breast cancer.Cancer cell international · 2025Review
- White Blood Cell Count Is Associated with Hyperuricemia in Patients with Type 2 Diabetes Mellitus.Journal of inflammation research · 2025Article
- The Potential Mechanism ofNutrients · 2024Article
- Mechanism and use strategy of uric acid-lowering drugs on coronary heart disease.International journal of cardiology. Heart & vasculature · 2024Review
- Article
- Correlation between gout and dry eye disease.International ophthalmology · 2024Review
- Hesperitin-Copper(II) Complex Regulates the NLRP3 Pathway and Attenuates Hyperuricemia and Renal Inflammation.Foods (Basel, Switzerland) · 2024Article
- Article
- Naturally occurring quercetin and myricetin as potent inhibitors for human ectonucleotide pyrophosphatase/phosphodiesterase 1.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperuricemia becomes a public health problem worldwide. It is not only a major risk factor for gout but also associated with the development of life-threatening diseases such as chronic kidney disease and cardiovascular diseases. Although there are several available therapeutic drugs, some serious adverse effects and contraindications are concerned. These drive the search for an alternative therapy that is effective and safe. Quercetin is of particular interesting since it has been reported numerous pharmacological activities, especially anti-hyperuricemia, antioxidant, anti-inflammation and amelioration of metabolic syndromes and cardiovascular diseases which are comorbidities of hyperuricemia and gout. In addition, quercetin has been widely used as a health supplement for many diseases however, the use for hyperuricemia and gout has not been indicated. Therefore, this review aims to gather and summarize published data regarding the efficacy in preclinical and clinical studies along with possible mechanism of action, and safety aspect of quercetin in order to support the use of quercetin as a dietary supplement for prevention and management of hyperuricemia and gouty arthritis and/or use as alternative or combination therapy to minimize the side effects of the conventional drugs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.